The estimated Net Worth of Chen Schor is at least $49.3 Milión dollars as of 16 April 2018. Mr. Schor owns over 2,000 units of resTORbio stock worth over $46,542,668 and over the last 13 years he sold TORC stock worth over $0. In addition, he makes $2,778,240 as President, Chief Executive Officer, Secretary a Director at resTORbio.
Sign up
Mr. Schor TORC stock SEC Form 4 insiders trading
Chen has made over 3 trades of the resTORbio stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of TORC stock worth $17,900 on 16 April 2018.
The largest trade he's ever made was buying 2,000 units of resTORbio stock on 16 April 2018 worth over $17,900. On average, Chen trades about 333 units every 0 days since 2011. As of 16 April 2018 he still owns at least 1,892,363 units of resTORbio stock.
You can see the complete history of Mr. Schor stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Chen Schor biography
Chen Schor CPA serves as President, Chief Executive Officer, Secretary, Director of the Company. Mr. Schor previously served as President, Chief Executive Officer and director of Synta Pharmaceuticals Corp. from May 2015 until its merger with Madrigal Pharmaceuticals in July 2016, and prior to that, from 2014 until 2016, Mr. Schor served as its Executive Vice President and Chief Operation Officer. From September 2012 to December 2014, Mr. Schor served as President and Chief Executive Officer of Novalere FP, Inc., a pre-commercial stage allergy therapeutics company. From September 2011 to October 2012, Mr. Schor served as Chief Business Officer of Eleven Biotherapeutics, an emerging therapeutics company. From March 2009 until September 2011, Mr. Schor served as Vice President of Business Development, global branded products at Teva Pharmaceuticals. Mr. Schor currently sits on the board of Brainstorm Cell Therapeutics Inc., a public biotechnology company. Mr. Schor received his MBA from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and a B.A. in Biology from Tel Aviv University.
What is the salary of Chen Schor?
As the President, Chief Executive Officer, Secretary a Director of resTORbio, the total compensation of Chen Schor at resTORbio is $2,778,240. There are no executives at resTORbio getting paid more.
How old is Chen Schor?
Chen Schor is 47, he's been the President, Chief Executive Officer, Secretary a Director of resTORbio since 2020. There are 6 older and no younger executives at resTORbio. The oldest executive at resTORbio, Inc. is Jeffrey Chodakewitz, 64, who is the Independent Director.
What's Chen Schor's mailing address?
Chen's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.
Insiders trading at resTORbio
Over the last 7 years, insiders at resTORbio have traded over $9,290,741 worth of resTORbio stock and bought 1,305,999 units worth $19,553,525 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Health Llc Pure Tech a Jonathan Silverstein. On average, resTORbio executives and independent directors trade stock every 69 days with the average trade being worth of $22,102,789. The most recent stock trade was executed by Health Llc Pure Tech on 18 December 2019, trading 6,161,531 units of TORC stock currently worth $7,393,837.
What does resTORbio do?
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
What does resTORbio's logo look like?
Complete history of Mr. Schor stock trades at Brainstorm Cell Therapeutics, Karyopharm Therapeutics Inc, Madrigal Pharmaceuticals Inc a resTORbio
resTORbio executives and stock owners
resTORbio executives and other stock owners filed with the SEC include:
-
Chen Schor,
President, Chief Executive Officer, Secretary, Director -
Lloyd Klickstein,
Chief Scientific Officer -
Jeffrey Chodakewitz,
Independent Director -
Yair Chaim Schindel,
Director -
Aya Jakobovits,
Director -
Carl Gordon,
Director -
Steve Dubin,
Director -
Erez Chimovits,
Director -
Don Healey,
Chief Technology Officer -
Francesco Galimi,
Senior Vice President and Chief Medical Officer -
Carrie Krehlik,
Chief Human Resource Officer, Senior Vice President -
Stewart Abbot,
Chief Operating Officer, Senior Vice President, Chief Scientific Officer -
Health Llc Pure Tech,
10% owner -
Advisors Llc Orbi Med Capit...,
-
John J Mccabe,
Vice President, Finance -
Meredith Manning,
Chief Commercial Officer -
Michael Grissinger,
Director -
Joan Mannick,
Chief Medical Officer -
Paul R. Fonteyne,
Director -
David Adam Steinberg,
Director -
Lynne Marie Sullivan,
Director -
Jonathan Silverstein,
Director